Adjuvant Radiation Boosts High-Risk Bladder Cancer Control
Adjuvant radiotherapy significantly reduces the risk of locoregional recurrence in patients with high-risk muscle-invasive bladder cancer. A study showed that patients receiving radiotherapy had better outcomes in disease-free and overall survival compared to those under observation. The findings suggest that incorporating adjuvant pelvic IMRT into standard treatment may enhance patient care with minimal added toxicity.
- ▪Adjuvant radiotherapy cut locoregional recurrence risk by more than half among patients undergoing radical cystectomy for high-risk muscle-invasive bladder cancer.
- ▪At 2 years, locoregional recurrence-free survival was 87.1% with radiotherapy compared to 76.0% with observation.
- ▪Serious adverse events were uncommon, with only 1.6% of radiotherapy patients experiencing severe toxicity.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/adjuvant-radiation-boosts-high-risk-bladder-cancer-control-2026a1000hg0?src=rss |
| Publication time | Wed, 27 May 2026 06:21:55 EDT |
| Retrieval time | 2026-05-27T10:37:58.859Z |
| Last seen | 2026-05-27T10:37:58.859Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 5JLm9cNWanUU |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Among patients undergoing radical cystectomy and perioperative chemotherapy for high-risk muscle-invasive bladder cancer (MIBC), adjuvant radiotherapy cut locoregional recurrence risk by more than half — with numeric improvements in disease-free and overall survival.METHODOLOGY:Locally advanced MIBC is treated with neoadjuvant chemotherapy followed by radical cystectomy and pelvic nodal dissection, yet about half of patients have disease recurrence within 3 years. Adjuvant radiotherapy can improve pelvic disease control and, with modern intensity-modulated radiotherapy (IMRT) planning, may do so more safely.Researchers conducted a phase 3 randomized controlled trial across four academic centers in India, enrolling 153 patients with nonmetastatic MIBC at high risk after radical…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
